信使核糖核酸技术在登革病毒疫苗研发中的机遇与挑战
Opportunities and challenges of mRNA technologies in development of dengue virus vaccine.
作者信息
Liu Xiaoyang
机构信息
Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States.
出版信息
Front Immunol. 2025 Mar 5;16:1520968. doi: 10.3389/fimmu.2025.1520968. eCollection 2025.
Dengue virus (DENV) is a mosquito-borne virus with a significant human health concern. With 390 million infections annually and 96 million showing clinical symptoms, severe dengue can lead to life-threatening conditions like dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The only FDA-approved vaccine, Dengvaxia, has limitations due to antibody-dependent enhancement (ADE), necessitating careful administration. The recent pre-approval of TAK-003 by WHO in 2024 highlights ongoing efforts to improve vaccine options. This review explores recent advancements in dengue vaccine development, emphasizing potential utility of mRNA-based vaccines. By examining current clinical trial data and innovations, we aim to identify promising strategies to address the limitations of existing vaccines and enhance global dengue prevention efforts.
登革病毒（DENV）是一种通过蚊子传播的病毒，对人类健康构成重大威胁。每年有3.9亿人感染，9600万人出现临床症状，严重登革热可导致危及生命的情况，如登革出血热（DHF）和登革休克综合征（DSS）。唯一获得美国食品药品监督管理局（FDA）批准的疫苗登革热疫苗（Dengvaxia）由于抗体依赖增强（ADE）存在局限性，因此需要谨慎接种。世界卫生组织（WHO）于2024年对TAK - 003的近期预批准凸显了在改善疫苗选择方面的持续努力。本综述探讨了登革热疫苗研发的最新进展，强调了基于mRNA的疫苗的潜在效用。通过研究当前的临床试验数据和创新成果，我们旨在确定有前景的策略，以解决现有疫苗的局限性并加强全球登革热预防工作。
Zotero 插件